The simplicity and efficiency of point of care diagnostics have revolutionised patient care. Current methods for measuring hypercoagulability often require trained technicians, large blood volumes, and result in long turnaround times. Standard testing for hypercoagulable disorders is performed in the central laboratory using automated coagulation analysers. However the trend is moving towards the development and implementation of point of care testing, as a result of the ever increasing number of patients on antithrombotic therapy. We present a novel microfluidic device and assay for monitoring the effect of two anticoagulants, unfractionated heparin (UFH) and low molecular weight heparin (LMWH). The assay is based on the anti-Xa assay principle but uses fluorescence detection. Our device is a disposable laminate microfluidic strip, fabricated from the cyclic polyolefin (COP), Zeonor®, which is extremely suitable for application to fluorescent device platforms. We present data on the execution of the anti-Xa assay in this microfluidic format, demonstrating that the assay can be used to measure both UFH and LMWH in human plasma samples from 0 to 1 U mL−1, with a rapid result obtained within 30–60 seconds.
展开▼
机译：即时诊断的简便性和效率彻底改变了患者的护理。当前用于测量高凝性的方法通常需要训练有素的技术人员，大量血液，并导致较长的周转时间。高凝性疾病的标准测试是在中央实验室使用自动凝血分析仪进行的。然而，由于抗血栓治疗的患者人数不断增加，趋势正在朝着即时检验的发展和实施迈进。我们提出了一种新型的微流控设备和测定法，用于监测两种抗凝剂，普通肝素（UFH）和低分子量肝素（LMWH）的作用。该测定基于抗Xa测定原理，但使用荧光检测。我们的设备是由环状聚烯烃（COP）Zeonor®制成的一次性层压微流体带，非常适合用于荧光设备平台。我们以这种微流体形式提供了有关执行抗Xa分析的数据，表明该分析可用于测量0至1 U mL-1的人类血浆样品中的UFH和LMWH，并在30天内获得快速结果–60秒。
展开▼
